PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) — Scout biographya biotechnology company that is revolutionizing companion animal medicine by providing a pipeline of point gene therapies and monoclonal antibodies for major chronic health conditions in companion animals, today announced that it will participate in the Morgan Stanley Animal Health Biopharma Global KOL Summit in New York on June 10, 2022.
President and CEO Mark Heffernan, Ph.D., will present the company’s background and strategy for providing a new standard of care for chronic diseases in companion animals. “The veterinary therapeutics market has experienced strong growth in recent years. Innovation and the dramatic increase in the number of pet owners seen during the pandemic are driving the anticipated growth acceleration,” said Dr. Heffernan. “Against this backdrop, Scout Bio is uniquely positioned to deliver this innovation through a diverse pipeline of novel biological therapies, including AAV-based gene therapies designed to provide long-lasting efficacy for major conditions such as diabetes, pain, allergies and anemia.
Scout Bio Board Member Aaron Schacht will provide industry-level context for the emergence of specialty biopharmaceuticals as a key growth area for veterinary therapeutics. Mr. Schacht is CEO of BiomEdit, a recently formed standalone company through the separation of Elanco’s microbiome R&D platform and pipeline, combined with the biological capabilities of Ginkgo Bioworks, focused on the innovation of new health products. animal. Elanco is the world’s second-largest animal health company with more than 10,000 employees and customers in more than 90 countries, where Mr. Schacht previously served as executive vice president with responsibilities over time including research oversight and global development, regulatory affairs and business development.
About Scout Bio
Scout Bio is a biotechnology company that is revolutionizing companion animal medicine by delivering a portfolio of point gene therapies and monoclonal antibodies for major chronic conditions in companion animals. Scout Bio’s therapies are designed to induce long-term expression of therapeutic proteins in companion animals using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is privately held and headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co
For more information, please contact: